The head of French drugmaker Sanofi-Synthelabo (SASY.PA: Quote, Profile, Research) sees no current reason to raise his hostile takeover bid for bigger rival Aventis (AVEP.PA: Quote, Profile, Research) and rules out a merger of equals, a newspaper reported on Wednesday.
